Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao, L Xiao… - The Lancet …, 2022 - thelancet.com
Background Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …
被引用次数：142 相关文章

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao… - The Lancet …, 2022 - ohsu.elsevierpure.com
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao… - The Lancet …, 2022 - mdanderson.elsevierpure.com
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

AO Kaseb, E Hasanov, HST Cao, L Xiao… - The lancet …, 2022 - europepmc.org
Background Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …
[PDF] researchgate.net

[PDF][PDF] Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao, L Xiao, JN Vauthey… - Lancet, 2022 - researchgate.net
Background Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao… - The lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …

[引用][C] Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao, L Xiao… - The Lancet …, 2022 - cir.nii.ac.jp
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable
hepatocellular carcinoma: a randomised, open-label, phase 2 trial | CiNii Research CiNii 国立 …

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao, L Xiao… - The Lancet …, 2022 - Elsevier
Background Hepatocellular carcinoma has high recurrence rates after surgery; however,
there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy …
[HTML] nih.gov

[HTML][HTML] Perioperative Nivolumab Monotherapy versus Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma: a randomised, open-label, phase 2 trial

AO Kaseb, E Hasanov, HST Cao, L Xiao… - The lancet …, 2022 - ncbi.nlm.nih.gov
Background Hepatocellular carcinoma (HCC) has high recurrence rates after surgery,
however, there is no standard of care neoadjuvant or adjuvant therapies. While …